Ovarian Hyperstimulation Syndrome Clinical Trial
Official title:
A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Single-centre Pilot Study Assessing the Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome
Assess the tolerability of quinagolide 200 μg/day in a dose-titration regimen in oocyte
donors undergoing controlled ovarian hyperstimulation and at risk of developing OHSS
Secondary Objectives
Estimate the effects of a quinagolide dose-titration regimen compared to placebo in
peritoneal fluid accumulation, incidence of ascites, OHSS symptoms and clinical laboratory
parameters of haemoconcentration
Status | Completed |
Enrollment | 30 |
Est. completion date | October 2008 |
Est. primary completion date | August 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 21 Years to 34 Years |
Eligibility |
Inclusion Criteria: 1. Signed Informed Consent Form, prior to screening evaluations 2. In good physical and mental health 3. Pre-menopausal females between the ages of 21-34 years (both inclusive) at the time of randomisation 4. Body mass index (BMI) between 18 and 29 kg/m2 (both inclusive) 5. Oocyte donor currently undergoing a controlled ovarian hyperstimulation cycle for assisted reproductive technologies (ART) 6. Antral follicle count = 20 Exclusion Criteria: 1. Any exclusion criteria for oocyte donation 2. Known clinically significant systemic disease (e.g., insulin dependent diabetes) 3. Known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) which can compromise participation in the study 4. Undiagnosed vaginal bleeding 5. Known tumours of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus 6. Malformations of the sexual organs incompatible with pregnancy 7. Positive pregnancy test prior to start of stimulation 8. Treatment with other dopamine agonists (ATC code N04BC) or dopamine antagonists (ATC code N05A) within 2 months prior to randomisation 9. Treatment with any hormonal therapy (except for thyroid medication and oral contraceptives and except that routinely used as part of the controlled ovarian hyperstimulation cycle), anti-psychotics (ATC code N05A), anti-depressants (ATC code N06), anxiolytics (ATC code N05B), hypnotics and sedatives (ATC code N05C) or continuous use of prostaglandin inhibitors (non-steroid anti-inflammatory drugs (NSAIDs), including aspirin) within 2 weeks prior to randomisation 10. Known hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption 11. Known history of psychotic disorders 12. Hypotension, orthostatic hypotension or recurrent syncope within 6 months prior to randomisation 13. Ongoing treatment of hypertension 14. Known previous poor tolerability to dopamine agonists 15. Known impaired hepatic or renal function 16. Current or past (12 months prior to randomisation) abuse of alcohol or drugs, and/or current (last month prior to randomisation) use of alcohol (more than 14 units per week) 17. Current or past (3 months prior to randomisation) smoking habit of more than 20 cigarettes per day 18. History of chemotherapy (except for gestational conditions) or radiotherapy 19. Use of any investigational drug during 3 months prior to randomisation 20. Previous participation in the study 21. Hypersensitivity to the active substance or to any of the excipients |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Instituto Valenciano de Infertilidad | Valencia |
Lead Sponsor | Collaborator |
---|---|
Instituto Valenciano de Infertilidad, IVI VALENCIA |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the tolerability of quinagolide 200 µg/day in a dose-titration regimen in oocyte donors undergoing controlled ovarian hyperstimulation and at risk of developing OHSS | 21 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00617864 -
The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome
|
N/A | |
Withdrawn |
NCT01979341 -
The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes
|
N/A | |
Completed |
NCT01427335 -
Calcium for Prevention of Ovarian Hyperstimulation Syndrome
|
Phase 3 | |
Completed |
NCT01014104 -
Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT00119925 -
'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"
|
N/A | |
Completed |
NCT06333691 -
Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin
|
N/A | |
Terminated |
NCT01714648 -
Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?
|
Phase 4 | |
Completed |
NCT01500863 -
Endometrial Receptivity After GnRH Agonist Triggering
|
Phase 4 | |
Recruiting |
NCT00417144 -
Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients
|
Phase 4 | |
Completed |
NCT03876145 -
The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome
|
N/A | |
Completed |
NCT05588635 -
Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy
|
||
Not yet recruiting |
NCT02392520 -
Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)
|
N/A | |
Completed |
NCT00835523 -
Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist
|
N/A | |
Active, not recruiting |
NCT05638529 -
Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome
|
Phase 4 | |
Not yet recruiting |
NCT03071172 -
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
|
Phase 3 | |
Recruiting |
NCT02084940 -
Long Acting GnRH Antagonist in PCOS Women Undergoing IVF
|
N/A | |
Completed |
NCT01815138 -
Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
|
Phase 4 | |
Completed |
NCT00867659 -
The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
|
N/A | |
Completed |
NCT01569256 -
Ovarian Hyperstimulation Syndrome and Cabergoline
|
N/A | |
Not yet recruiting |
NCT05198128 -
Ovarian Hyperstimulation Syndrome Using Calcium Infusion
|
N/A |